Fig 1.
(A) The percentages of patients based on the initial lesion localisation and (B) the percentages of the initial symptom types in the favourable (ARMSS score <5) and unfavourable course (ARMSS score ≥5) groups of the prospective MS cohort.
Fisher’s exact test. *, P<0.05; **, P<0.01.
Table 1.
Demographic and clinical characteristics of the prospective MS cohort.
Table 2.
Rules and their predictive properties for the long-term disease outcome identified by the genetic algorithm.
Fig 2.
Differences in cerebrospinal fluid (A) alpha-2-macroglobin, (B) apolipoprotein A1, (C) CD36, and (D) haptoglobin levels between the favourable and unfavourable course groups in the verification MS cohort, measured by enzyme-linked immunosorbent assays.
Two-tailed Student’s t-test; P<0.05, significant. ARMSS, age-related MS severity.